Table 3.
Baseline Characteristics and Events During Follow‐up of Men in the Study Sample According to Deciles of ASCVD Risk Based on the ACC/AHA Calculator
| Predicted ASCVD Risk Decile | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| n | 339 | 340 | 340 | 339 | 340 | 340 | 339 | 340 | 340 | 339 |
| Age, y | 44 (3) | 46 (3) | 48 (4) | 50 (5) | 52 (5) | 53 (6) | 55 (6) | 58 (7) | 61 (7) | 66 (7) |
| Systolic blood pressure, mm Hg | 117 (11) | 122 (13) | 123 (13) | 124 (13) | 127 (15) | 128 (15) | 129 (15) | 134 (16) | 138 (17) | 148 (18) |
| Diastolic blood pressure, mm Hg | 77 (8) | 80 (10) | 80 (10) | 82 (9) | 82 (10) | 82 (9) | 82 (10) | 83 (10) | 82 (11) | 83 (11) |
| Treatment for hypertension, n (%) | 8 (2) | 22 (6) | 26 (8) | 36 (11) | 44 (13) | 43 (13) | 57 (17) | 80 (24) | 101 (30) | 178 (53) |
| Total cholesterol, mg/dL | 187 (29) | 203 (34) | 204 (35) | 210 (33) | 217 (35) | 213 (36) | 216 (37) | 219 (38) | 218 (39) | 214 (43) |
| HDL‐C, mg/dL | 53 (12) | 48 (12) | 47 (12) | 46 (12) | 46 (12) | 44 (13) | 42 (12) | 43 (12) | 42 (12) | 41 (11) |
| LDL‐C, mg/dL | 118 (27) | 134 (30) | 134 (32) | 139 (31) | 146 (32) | 144 (35) | 146 (34) | 146 (36) | 147 (38) | 141 (38) |
| LDL‐C <70 mg/dL, n (%) | 6 (2) | 5 (1) | 5 (1) | 3 (1) | 0 (0) | 6 (2) | 4 (1) | 6 (2) | 0 (0) | 4 (1) |
| Triglycerides, mg/dL | 83 (41) | 108 (62) | 115 (63) | 127 (67) | 126 (61) | 124 (63) | 140 (67) | 154 (75) | 152 (74) | 160 (77) |
| Diabetes, n (%) | 1 (0.3) | 2 (0.6) | 5 (1.5) | 5 (1.5) | 2 (0.6) | 14 (4) | 14 (4) | 21 (6) | 42 (12) | 111 (33) |
| Current smokers, n (%) | 7 (2) | 27 (8) | 55 (16) | 87 (26) | 103 (30) | 136 (40) | 132 (39) | 140 (41) | 118 (35) | 99 (29) |
| Pooled risk, % (minimum to maximum) | 1.3 (0.3 to 1.9) | 2.5 (1.9 to 3.0) | 3.6 (3.0 to 4.3) | 5.1 (4.3 to 5.9) | 6.6 (5.9 to 7.4) | 8.3 (7.4 to 9.3) | 10.5 (9.3 to 12.1) | 13.7 (12.1 to 15.6) | 18.0 (15.6 to 21.2) | 30.4 (21.2 to 67.7) |
| Eligible for statin therapy, n (%) | 4 (1) | 12 (4) | 20 (6) | 30 (9) | 31 (9) | 307 (90) | 335 (99) | 334 (98) | 340 (100) | 335 (99) |
| Follow‐up | ||||||||||
| Observed risk, % (95% CI) | 0.6 (−0.2 to 1.4) | 2.6 (0.9 to 4.4) | 3.5 (1.6 to 5.5) | 5.0 (2.7 to 7.3) | 8.5 (5.5 to 11.5) | 6.5 (3.8 to 9.1) | 7.7 (4.8 to 10.5) | 11.5 (8.1 to 14.9) | 14.7 (10.9 to 18.5) | 23.0 (18.5 to 27.5) |
| New‐onset lipid therapy on follow‐up, n (%) | 9 (3) | 17 (5) | 25 (7) | 40 (12) | 42 (12) | 44 (13) | 63 (19) | 50 (15) | 74 (22) | 91 (27) |
| Censored due to death from non‐ASCVD causes, n (%) | 5 (1) | 7 (2) | 6 (2) | 9 (3) | 7 (2) | 16 (5) | 25 (7) | 24 (7) | 38 (11) | 60 (18) |
Data are presented as mean (SD) or numbers (percentages) unless otherwise specified. New‐onset lipid therapy refers to numbers of participants within each group initiating statin therapy. Sample eligible for statin therapy is based on the new risk calculator and 2013 guidelines. ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol.